Acrylamide moiety is a pronounced Michael acceptor that has drawn much interest in a wide array of drugs designed for various therapeutic purposes. Herein we outline different synthetic pathways, scientific bases for its chemical reactivity and how it is functionalized for design of new therapeutic entities, in addition to a brief insight into spectrum of reported biological activities of acrylamide containing compounds up to date.
INTRODUCTION
Acrylamide moiety has been proved to be a valuable tool for design of novel therapeutic entities. Evidence for that is observed through the wide range of biological activities exhibited by acrylamide derivatives including antitumor activity 1 , epidermal growth factor receptor (EGFR) kinase inhibitor activity 2 , antiviral activity 3 , anti-inflammatory activity 4 , antiplatelet activity 5 , antidiabetic activity 6 , tubulin polymerization inhibitor activity 7 , antibacterial activity 8 , vasodilator activity 9 , antifungal activity 10 , angiotensin II receptor antagonist activity 11 and histone deacetylase HDAC inhibitor activity 12 . A considerable number of approved drugs incorporate acrylamide moiety in their structures, for example: Entacapone a catechol Omethyl transferase (COMT) inhibitor used for treatment of Parkinson disease. In addition, Panobinostat a HDAC inhibitor approved in February 2015 for the treatment of multiple myeloma. In the same context Belinostat HDAC inhibitor approved in July 2014 for treatment of peripheral T-cell lymphoma. Additionally, Ibrutinib, a Bruton's tyrosine kinase BTK inhibitor approved 2013 for treatment of various myeloid tumors. Rifampicin, a well-known antibiotic approved for treatment of mycobacterial infections as tuberculosis and leprosy. Anthramycin an antibiotic and antineoplastic drug. Afatinib EGFR kinase approved for treatment of non-small cell lung cancer (NSCLC), Carnetinib and Dacomitinib EGFR kinase inhibitors phase II clinical trials drugs for treatment of NSCLC 
Synthetic pathways

Knovenagel condensation
Knovenagel originally reported the condensation of aldehydes with diethyl malonate in basic medium to yield alkylidene malonic acid diesters 13 , Scheme 1. Dobner reported the modification of Knovenagel condensation by carrying out the reaction between aldehydes and malonic acid in Another applied modification of Knovenagel condensation for synthesis of substituted acrylamides is the reaction of aldehydes with acetamides substituted with an electron withdrawing group at position no. 2 under basic conditions to yield 2,3-disubstituted acrylamide derivatives. The most common is the reaction of the desired aldehyde with N-substituted 2-cyanoacetamide derivatives to yield various desired 2-cyanoacrylamide derivatives 1, [16] [17] [18] , Scheme 3.
Scheme 3. Knovenagel condensation between aldehydes and N-substituted 2-cyanoacetamide derivatives to yield 2-cyanoacrylamide derivatives
Augustine 19 et al. reported the synthesis of a series of 3-substituted acrylic acid derivatives with excellent yields using a modification of knovenageldobner reaction in which germinal dibromomethylarenes were used as alternatives for noncommercially available aldehydes, the obtained acrylic acid derivatives can be easily converted to the corresponding desired acrylamide derivative via reaction with appropriate primary amine, Scheme 4. Scheme 4. Modified Knovenagel Dobner reaction using germinal dibromomethylarenes as alternative for aldehydes
Via Horner-Wadsworth-Emmons (HWE) reaction
Applying the principle of HWE reaction 20,21 , (E) 3-substituted acrylamide derivatives can be obtained where desired aldehydes or ketones are reacted with acetate esters bearing a phosphonate ester derivative at alpha carbon (2-(phosphonate ester)-acetate ester derivatives) that were previously activated using strong bases as sodium hydride to yield (E) 3-substituted acrylate esters. The formed (E) 3-substituted acrylate esters undergo either alkaline hydrolysis of ester to give the free acrylic acid followed by reaction with various primary amines to yield the desired 3-substituted acrylamide or direct refluxing the formed 3-substituted acrylate esters with desired primary amine to yield the 3-substituted acrylamide 9, 22 , scheme 5.
Via Mizoroki-Heck coupling reaction:
The principle of Mizoroki-Heck coupling reaction 23,24 is also applied for synthesis of the 3-substituted acrylamide derivatives. It involves Palladium catalyzed reaction of aryl or aryl halides with acrylic acid esters yielding 3-substituted acrylate esters. The formed 3-substituted acrylate esters undergo both alkaline hydrolysis and reaction of the formed free acid with various primary amines or directly refluxing the formed 3-substituted acrylate esters with desired primary amine to yield the desired 3-substituted acrylamide 25,26 , Scheme 6.
Via reaction between 2-cyanoacetamides and aryl isothiocyanates
Another widely applied synthetic methodology is via the reaction between 2-cyanoacetamide derivatives and aryl isothiocyanates under basic conditions to yield a thiolate intermediate which is alkylated using methyl iodide or dimethyl sulfate to yield 3-aryl, 2-cyano, 3-methylthio acrylamide derivatives 27,28 , Scheme 7. 
Via reaction between 2-cyanoacetamides and carbon disulfide
Acrylamide reactivity and its functionalization for design of new therapeutic entities
The reactivity of acrylamide moiety has been extensively investigated; it depends mainly on being Michael acceptor. This results from the presence of α, β-unsaturated carbonyl where the α, β-unsaturated moiety represents the electrophilic center required for Michael addition reaction of various nucleophiles as illustrated in Figure 2 . This unique property is especially helpful for design of new therapeutic entities where acrylamide moiety can be functionalized for efficient targeting of different proteins which possess nucleophilic residues as cysteine and serine at active drug binding site [31] [32] [33] [34] . 
Advantage of additional nitrile substitution at the alpha carbon
An additional nitrile group at the alpha carbon of acrylamide (2-cyanoacrylamide) can increase the efficiency of acrylamide moiety as a tool for designing successful drugs addressing protein targets rich in nucleophilic residues and H-bond donor residues. This additional group forms "nitrile trap" which traps both nucleophilic residues and H-bond donor residues, for nucleophilic residues it undergoes nucleophilic addition at the electrophilic carbon of nitrile whereas for H-bond donor residues it serves as H-bond acceptor via the lone pair on the nitrogen of nitrile group. The advantage of nitrile moiety as a tool for designing various molecules addressing various therapeutic targets was highlighted by many researchers [35] [36] [37] [38] [39] [40] .
Acrylamides a tool for design of targeted covalent inhibitors TCI's
TCI's are small molecules bearing specific functional groups capable of covalent binding with specific residues at target proteins leading to silencing and inhibition of the protein action. Design of TCI's is a successful strategy for developing new drugs [40] [41] [42] [43] , a fact empathized through the well appreciated record of successful drugs belonging to this class of compounds. For example: penicillins and cephalosporins the beta lactam antibiotics exert covalent inhibition to bacterial trans-peptidase enzyme a pivotal for bacterial cell wall synthesis leading to the bactericidal effect. Figure 3 and Figure 4 respectively. and evaluated them for their angiotensin II receptor antagonist activity. A structure activity relationship study was generated revealing that substitution of imidazole at the 4-position with the N-methyl, 3, 3-dimethylacrylamide group resulted in enhanced activity. Compound 1 was superior to the reference drug in vitro but with poor in vivo activity after oral administration. To overcome this problem prodrug esters were synthesized and evaluated; among which compound 2 (the -[(ethoxycarbonyl)oxy]ethyl ester) exhibited highest in vivo activity after oral administration.
Keenan 50 et al reported synthesis of a set of substituted (E) -acrylic acid derivatives for evaluation of their activity as angiotensin II receptor. They were guided by a developed pharmacophore model which suggests that the addition of acid chain and an aryl side chain to imidazole mimicking the C-terminal phenylalanine region of native ligand would lead to increased activity. A SAR study was developed which revealed that electron-rich hetero aryl rings improved the activity. Compound 3 was the most potent orally bioavailable candidate. . AMG9810 blocked TRPV1 activation in all models of TRPV1 activation at nanomolar concentrations (IC50 range 15.8-294 nM for different models).
Antidiabetic activity
Li 54 et al reported discovery of set of 3-phenyl acrylamide derivatives developed at GlaxoSmithKline GSK as novel potent human liver glycogen phosphorylase a (HLGPa) inhibitors via highthroughput screening. The discovered compounds possess an extreme advantage of being glucosesensitive where they exhibited activity at high blood glucose levels and no or minimal activity when blood glucose level decreases. The most active compounds were compound 8 (IC50 0.94 μM) and compound 9 (IC50 0.17 μM).
Onda 6 et al reported synthesis of a series of 3-(3,4-dichlorophenyl)acrylamide derivatives and their evaluation for human liver glycogen phosphorylase A (HLGPa) inhibitory activity. Compound 10 was most active (IC50 0.023 μM). X-ray crystallography study of the enzyme complexed with compound 10 revealed that compound 10 exhibited hydrophobic interaction with the enzyme via the 3,4-dichlorophenyl moiety.
Prostaglandin E2 receptor-3 EP3
antagonist activity 3-Acrylsulfonamide-4-aryloxy indole series was synthesized and evaluated for prostaglandin E2 receptor-3 EP3 antagonist activity by Zhou 5 et al. EP3 is associated with prostaglandin E2 induced platelet aggregation 55 , thus EP3 antagonism would produce antiplatelet activity without inhibiting PGE2 production which is a main drawback of conventional treatments. Synthesized derivatives were evaluated for IC50 of human EP3 receptor binding among which compounds 11, 12 and 13 showed highest potency with IC50 of 2.6 nM, 3.5 nM and 4.6 nM; respectively. 
Diacyl glycerol transferase DGAT inhibitor activity
Hepatic DGAT represents a potential target for treatment of obesity and fatty liver disorders 57 . lee 58 et al reported synthesis of series of indolyl acrylamides and evaluation for their DGAT inhibitory activity. Compound 17 exhibited highest potency with IC50 of 2.5μM inhibiting synthesis of triglyceride in dose dependent manner. The study revealed the selectivity of indolyl acrylamides against DGAT-2.
3.7. Soluble guanylyl cyclase sGC activator activity sGC is an enzyme responsible for cellular conversion of guanosine triphosphate (GTP) into cyclic guanosine mono phosphate cGMP. It serves as a receptor for nitric oxide (NO) and cellular transduction pathway for physiological NO induced vasodilator effects. sGC activators are identified as targets for novel vasodilator drugs. Zhang 9 et al reported the synthesis of set of O-substituted 3-aryl acrylamides. Synthesized compounds exhibited EC50 ranging (2.9-100 μM) compound 18 was the most active with EC50 2.9 μM.
COX II inhibitor activity
Yao 59 et al reported the synthesis of series of novel resveratrol amides including acrylamide derivatives and evaluation of their cyclooxygenase-2 (COX-2) inhibitory activity. Among various amides acrylamide derivatives showed the highest activity. Compounds 19 and 20 exhibited the most potent COX-2 inhibitory activity with the IC50 values of 1.02 and 1.98 μM, respectively. Molecular docking studies were carried out for 20 and 21 into COX-2 active site revealing the interaction via strong hydrophobic interactions and hydrogen bonding.
NLRP3 inflammasome inhibitor activity
NLRP3 inflammasome is an oligoprotein complex coded by NLRP3 gene, thus nominated after it. It is expressed mainly in myeloid tissue and macrophages as a part of innate immunity. It is involved in inflammatory response to different pathogens and inflammatory situations. Its role involves a caspase-1 activity for activation of chemokines as IL-1β and induction of chemotaxis, as well as roles in induction of necrosis and pyroptotic cell death 60 . Aberrations of NLRP3 inflammasome activity have been linked to number of diseases as neurological disorders 61 , Alzheimer's disease 62 , auto-immune disorders 63 and inflammatory disorders 64 . Cocco 65 et al. reported synthesis of a set of acrylamide derivatives and evaluation for their activity as NLRP3 inflammasome inhibitors, including assay for inhibition of I IL-1β release from macrophages including mutant subtypes, then the most active compounds were further evaluated for NLRP3 ATPase activity. Compound 21 was the most active ,it inhibited the NLRP3 ATPase activity in concentration dependent manner with IC50 of 74 μM , it was further evaluated for binding mode and ligand interaction with ATP binding pocket of ATPase activity domain of NLRP3 inflammasome via computational docking study which proposed a covalent interaction with cysteine 419 residue , hydrogen bond between tyrosine 381 and oxygen of carbonyl group, whereas the phenyl sulfonamide group exhibited hydrogen bonding and charge-transfer interactions with lysine 232, threonine 233, arginine 237, and histidine 522.
Chemokine receptor 3 CCR3
antagonist activity CCR3 is a receptor for inflammatory chemokines as eaotaxin, MCP (monocyte chemoattractant protein) and RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted), it is expressed mainly on eosinophils 66 . It is involved in the chemotaxis of eosinophils in different inflammatory and allergic diseases thus represents potential target for addressing inflammatory and allergic diseases 67 . Sato 4 et al. reported synthesis and characterization of acrylamide derivatives with potent CCR3 inhibitory activity and evaluation of in vitro metabolic stability in human liver microsomes expressed as clearance rate (CLint; mL/min/kg) of these compounds. A SAR study was generated for both CCR3 antagonism activity and CLint values .compound 22 was among potent inhibitors (IC50 = 8.4 nM) with highest metabolic stability (Clint <64 mL/min/kg).
Antitumor activity:
Zhou et al. reported synthesis of a set of 3-aryl, 2-cyanoacrylamide derivatives and evaluation of their anti-tumor activity against human nasopharyngeal carcinoma cell line KB, human gastric carcinoma cell line BGC-823 and human hepatoma cell line BEL-7402. Compound 23 was the most potent with IC50 values of 5.6 μg/mL for human gastric carcinoma cell line BGC-823, 13.1 μg/mL for human nasopharyngeal carcinoma cell line KB and 12.5 μg/mL for human hepatoma cell line BEL-7402. 
Tubulin polymerase inhibition activity
Tubulin polymerase enzyme is an essential enzyme for synthesis of microtubules a crucial cellular protein for mitotic division, thus it represents valuable target for development of antitumor agents. Borrel 74 et al. reported synthesis of series of derivatives of combretastatin A4 a well-defined tubulin polymerase inhibitor 75 . The new derivatives included acrylamide derivatives and evaluated their cytotoxic effects against IGROV, KB-3-1 and MCF-7cancer cell lines. Tubulin polymerization inhibitory activity was also evaluated. Potent inhibitory activity was observed for acrylamide derivatives. Compound 33 the most potent cytotoxic agent exhibited activity against tubulin polymerase with an IC50 1.5 fold IC50 of colchicine.
HDAC inhibitor activity
Histones are the nuclear proteins responsible for packing DNA into nucleosome complex. The regulation of almost all cellular activities starts by activation of specific nucleosomes via acetylation and deacetylation of the lysine residue of histone. The process of acetylation and deacetylation is catalyzed by family of enzymes known as histone deacetylases. 79 applying principles of non-classical isosterism. All synthesized compounds were evaluated for HDAC inhibitory activity and cytotoxic activity against colon cancer cell line HCT 116, breast cancer cell line MCF-7 and pulmonary adenocarcinoma cell line A549. All compounds exhibited superior antitumor effect. Compound 34 was most potent with IC50 of 0.118 µM, 1.258 µM, 2.871 µM and 0.723 µM for HDAC-1 inhibitory assay; cytotoxicity assay for HCT-116, MCF-7 and A549 cancer cell lines; respectively. Assay of pharmacokinetic profile was conducted for compound 35 which showed bioavailability of 76% in rat model.
Protein kinase inhibitor activity
Protein kinases represent a huge family of cellular enzymes which are pivotal in signal transduction pathways that control numerous cellular functions, including proliferation, differentiation, migration, apoptosis, and angiogenesis 80 . protein kinase enzymes represent a potential target for TCI's as a result of the high density of nucleophilic residues at active sites of protein kinases. As formerly mentioned numerous approved drugs with protein kinase inhibitory activity incorporate acrylamide moiety. In continuation for this promising activity several research papers reported the activity of different acrylamide derivatives against different kinases.
EGFR kinase inhibitory activity
EGFR is a transmembrane receptor tyrosine kinase which plays central role in cell adhesion, migration proliferation and differentiation via different signal transduction pathways 81 . Up-regulated EGFR signaling has been linked to a variety of tumor progression to metastasis and invasion; thus EGFR is a potential target for treatment of cancer 82 . Mutations in EGRF has been reported to be linked to resistance to conventional 1 st generation EGFR kinase inhibitors as gefitinib causing serious relapse of therapy. For instance exon 19 deletion mutation (labeled EGFR Del ), substitution mutation L858R (labeled as EGFR L858R ), substitution mutation T790M (labeled as EGFR T790M ), mutation including both double exon 19 deletion and T790M (labeled as EGFR T790M/Del ) and mutations involving both L858R and T790M (labeled as EGFR L858R/T790M ) arouse which required development of more potent generations 83 . Rauh 82 et al. reported the design, synthesis and evaluation of novel EGFR kinase inhibitors targeting mutant types of EGFR kinase. The design was based on the scaffold of WZ4002 a third generation EGFR kinase inhibitor exhibiting high potency against Mutant EGFR kinases EGFR L858R and EGFR T790M 83 . The designed analogues included modification of WZ4002 structure by introducing certain substitutions at positions no.2 and 3 of the terminal acrylamide. In position no.2 they introduced cyano and trifluoromethyl electron withdrawing groups. In position no.3 they introduced different aliphatic and aromatic groups. Based on the obtained IC50 values a SAR study was generated. The 2-cyano derivatives exhibited much higher activity than the corresponding 2-triflouromethyl analogues; this was attributed to steric repulsions of the bulkier trifluoromethyl group with Arg841 of EGFR kinase. The designed derivatives were highly selective for the mutant types while much less active towards the wild type EGFR a property which WZ4002 lacks. . The non-mutated ABL gene codes for normal functioning membrane tyrosine kinase involved in mitotic pathway. Under physiologic conditions the function of ABL coded tyrosine kinase is regulated and controlled, whereas the mutated BCR-ABL kinase is unregulated and act in an always-on mode leading to uncontrolled cell division. BCR-ABL kinase mutation as associated with chronic myeloid leukemia 88 . 
